Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
The historical rank and industry rank for Anika Therapeutics's Median PS Value or its related term are showing as below:
STU:AKP'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.28 Med: 0.75 Max: 2.41
Current: 0.61
During the past 13 years, the highest Price to Median PS Value of Anika Therapeutics was 2.41. The lowest was 0.28. And the median was 0.75.
STU:AKP's Price-to-Median-PS-Value is ranked better than 71.79% of 560
companies
in the Drug Manufacturers industry
Industry Median: 0.87
vs STU:AKP: 0.61
Anika Therapeutics (STU:AKP) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Anika Therapeutics's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
17.80
/
29.26
=
0.61
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anika Therapeutics Median PS Value Related Terms
Anika Therapeutics Median PS Value Historical Data
* Premium members only.
The historical data trend for Anika Therapeutics's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:AKP vs EBS, ELTP, AKBA: Median PS Value Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Anika Therapeutics's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anika Therapeutics Price-to-Median-PS-Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Anika Therapeutics's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Anika Therapeutics's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 3.937.
Anika Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €7.432.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anika Therapeutics (STU:AKP) has a Median PS Value of €29.26 as of Sep. 14, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Anika Therapeutics and its competitors. According to the industry distribution chart, Anika Therapeutics ranks #158 out of 560 companies in the Drug Manufacturers industry, placing it in the top 28.2%.
Is Anika Therapeutics' Median PS Value too high?
Anika Therapeutics' current Median PS Value is €29.26. Based on the distribution chart, Anika Therapeutics ranks #158 out of 560 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Anika Therapeutics has a GF Score™ of 66/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Anika Therapeutics' Median PS Value compare to EBS and ELTP?
According to the Drug Manufacturers industry distribution chart, Anika Therapeutics ranks #158 out of 560 companies for Median PS Value. This puts Anika Therapeutics in the upper half of its industry. The industry median Median PS Value is 0.87. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Drug Manufacturers company?
The median Median PS Value among Drug Manufacturers companies is 0.87, based on 560 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Anika Therapeutics and its competitors. For the Drug Manufacturers industry, the median Median PS Value is 0.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Anika Therapeutics's current Median PS Value is €29.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anika Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Anika Therapeutics (STU:AKP) is currently considered Fairly Valued. The stock's GF Value™ is €16.76, compared to a current price of €17.80 — trading 6.2% above its estimated fair value. The current Median PS Value is €29.26. Anika Therapeutics' overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Anika Therapeutics (STU:AKP), the current Median PS Value is €29.26 as of Sep. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Anika Therapeutics (STU:AKP) Overvalued in 2026?
Based on GuruFocus' analysis, Anika Therapeutics stock appears to be overvalued.
The current stock price of €17.80 is trading 6.2% above its estimated GF Value™ of €16.76.
GuruFocus considers Anika Therapeutics to be Fairly Valued.
Key valuation signals for STU:AKP:
Median PS Value: €29.26
GF Value™: €16.76 vs. price of €17.80 (6.2% above fair value)
No single metric tells the full story. See the STU:AKP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Anika Therapeutics Inc operates in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company leverages proprietary hyaluronic acid (HA) technology to develop differentiated products and provides products and services. Its OA Pain Management products include Orthovisc, Monovisc, and Cingal. Monovisc and Orthovisc are single- and multi-injection HA viscosupplement products indicated for pain relief from OA conditions and are generally administered to patients in an office setting. In the United States, Monovisc and Orthovisc are marketed exclusively by Johnson & Johnson MedTech. It generates maximum revenue from the OEM Channel and derives the majority of its revenue from the United States, with a presence in Europe and other countries.
66GF Score
Get the complete analysis for STU:AKP
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:AKP has been successfully added to your 
